Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retlirafusp Alfa + Apatinib + Nab-Paclitaxel in Immunotherapy-Pretreated Gastric/GEJ Cancer
NCT07610629Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- May 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of retlirafusp alfa in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Henan Cancer Hospital. Primary endpoint: Objective Response Rate. Planned start May 2026; status: not yet recruiting.
02
Drugs
retlirafusp alfa
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07610629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07610629.